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We conducted a nested case-control study within a cohort of 6244 patients to assess risk factors for avascular
necrosis (AVN) of bone in children and adolescents after allogeneic transplantation. Eligible patients were
21 years of age, received their ﬁrst allogeneic transplant between 1990 and 2008 in the United States, and
had survived  6 months from transplantation. Overall, 160 patients with AVN and 478 control subjects
matched by year of transplant, length of follow-up and transplant center were identiﬁed. Patients and control
subjects were conﬁrmed via central review of radiology, pathology, and/or surgical procedure reports. Median
time from transplant to diagnosis of AVN was 14 months. On conditional logistic regression, increasing age at
transplant (5 years), female gender, and chronic graft-versus-host disease (GVHD) were signiﬁcantly
associated with increased risks of AVN. Compared with patients receiving myeloablative regimens for ma-
lignant diseases, lower risks of AVN were seen in patients with nonmalignant diseases and those who had
received reduced-intensity conditioning regimens for malignant diseases. Children at high risk for AVN
include those within the age group where rapid bone growth occurs as well as those who experience
exposure to myeloablative conditioning regimens and immunosuppression after hematopoietic cell trans-
plantation for the treatment of GVHD. More research is needed to determine whether screening strategies
speciﬁcally for patients at high risk for developing AVN with early interventions may mitigate the morbidity
associated with this complication.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Avascular necrosis (AVN) of the bone is a debilitating late
complication of allogeneic hematopoietic cell transplantation
(HCT) that can be associated with signiﬁcant morbidity [1,2].
The incidence and risk factors for AVN have been well
described in adult transplant recipients with an estimatededgments on page 591.
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13.12.567cumulative incidence of 3% to 10% at 5 years after trans-
plantation [1,3-9]. Graft-versus-host disease (GVHD), expo-
sure to corticosteroids or calcineurin inhibitors, cumulative
dose of corticosteroids, older age, female gender, and use of
total body irradiation (TBI) as part of conditioning regimen
have been identiﬁed as risk factors for AVN in adult HCT re-
cipients. Although its pathogenesis is poorly understood,
potential mechanisms for development of AVN include local
vascular damage that leads to increased marrow edema and
ischemia, ineffective osteoblastic repair processes due to
metabolic factors, and mechanical stresses [1,10].
Large studies speciﬁcally focusing on evaluating risk fac-
tors for AVN in pediatric HCT survivors are lacking. Factors
such as immaturity and ongoing growth of bones and
endocrine dysfunction related to growth and sex hormones
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in a different way from adults. Hence, extrapolating ﬁndings
from studies that have only included adults or have combined
adults with children can be a challenge. Also, it is not known
whether the relatively recent less toxic preparative regimens
(nonmyeloablative and reduced-intensity conditioning) are
associated with lower risks of AVN than conventional mye-
loablative regimens in this population. To better understand
the risk factors for AVN after allogeneic HCT in children and
adolescents, we conducted a case-control study using data
from the Center for International Blood and Marrow Trans-
plant Research (CIBMTR). We evaluated risk factors from
both “older approaches” (myeloablative regimens, greater
use of sibling donors) and “contemporary approaches”
(nonmyeloablative/reduced intensity regimens, greater use
of unrelated donors) in our analysis.
METHODS
Data Source
The CIBMTR is a working group of more than 450 transplantation cen-
ters worldwide that contribute detailed data on HCTs to a Statistical Center
at the Medical College of Wisconsin in Milwaukee and the National Marrow
Donor Program in Minneapolis. Participating centers are required to report
all transplants consecutively, and patients are followed longitudinally.
Computerized checks for discrepancies, physicians’ review of submitted
data, and onsite audits of participating centers ensure data quality. Data are
collected before transplant, 100 days and 6 months after transplant, and
annually thereafter, or until death. The follow-up research forms speciﬁcally
inquire whether a recipient has developed AVN post-transplantation.
Observational studies conducted by the CIBMTR are performed under the
guidance of the Institutional Review Board of the National Marrow Donor
Program and are in compliance with all applicable federal regulations per-
taining to the protection of human research participants.
Patients
For our study, we selected ﬁrst allogeneic HCT recipients aged  21 years
at transplantation who had been reported to the CIBMTR between 1990 and
2008. Because screening and management practices for AVN can vary by re-
gion, we restricted our cohort to patients who had received their transplant at
a center in the United States. We also limited our cohort to patients who had
survived at least 6 months or more after transplantation because our analysis
was focused on long-termHCTsurvivors and on transplant-related risk factors
for AVN. Patients with any diagnosis and recipients of bothmyeloablative and
reduced-intensity/nonmyeloablative regimens were eligible.
Selection of Patients and Control Subjects
Overall, 6244 patients met study eligibility criteria and were the basis
for selection of patients and control subjects for our study. Patients were
those who had a diagnosis of AVN reported on post-transplant follow-up.
AVN of any joint was considered. For all cases identiﬁed as potential patients,
we requested diagnostic and/or treatment information from centers to
ascertain the diagnosis of AVN (eg, copies of radiologic investigations, pa-
thology reports, or surgical operative notes). We excluded 2 patients from
our analysis for whom we were not able to conﬁrm the diagnosis of AVN
from their transplant center.
We established a pool of control subjects using eligible patients who had
received their transplant at the same centers as patients and did not have a
diagnosis of AVN reported to the CIBMTR. For each patient we chose a control
subject that was matched by year of transplantation (1 year) and follow-up
duration (follow-up post-transplant no less than the interval from HCT to
onset of AVN for the corresponding patient). Control subjects were selected
from the same center as patients, if available. If a control subject could not be
identiﬁed for a patient from the same center, control subjects were selected
from another center that had patients with AVN included in this study.
Each patient was matched with up to 3 control subjects. For patients
with several matched control subjects, 3 were selected randomly for the
analysis. For each selected control subject, we contacted transplant centers
and requested them to review medical records and conﬁrm that the patient
did not have AVN. On this review, 4 control subjects were identiﬁed to have
AVN post-transplantation and were subsequently considered as patients.
Control subjects were excluded from the analysis if they had a pre-HCT
diagnosis of AVN (n ¼ 1) or if centers were not able to conﬁrm the
absence of AVN diagnosis (n ¼ 26).
We identiﬁed 160 conﬁrmed patients with AVN and 478 matched con-
trol subjects. Among these case-control pairs, 407 (85%) were matchedwithin the same center as the patient. One hundred ﬁfty nine patients had 3
matched control subjects, and 1 patient had 1 matched control subject.
Study Deﬁnitions and Statistical Analysis
Conditioning regimens were deﬁned as myeloablative, reduced intensity,
and nonmyeloablative using established guidelines [11]. Because no clear
guidelines exist for classifying conditioning regimens for nonmalignant dis-
eases, these diseases were considered as a separate categorywhen describing
conditioning regimen intensity. Disease status for malignant diseases was
assigned as early, intermediate, or advanced [12]. Early disease included
acute myeloid leukemia or acute lymphoblastic leukemia in ﬁrst complete
remission, chronic myeloid leukemia in ﬁrst chronic phase, myelodysplastic
syndrome refractory anemia, or refractory anemiawith ringed sideroblasts or
unspeciﬁed myelodysplastic syndrome with <5% marrow blasts. Patients
with acute myeloid leukemia or acute lymphoblastic leukemia in second or
greater remission, chronic myeloid leukemia in second or greater chronic
phase, or chronic myeloid leukemia in accelerated phase were classiﬁed as
intermediate-risk disease. All other patients, including patients with lym-
phoma, were classiﬁed as advanced disease. The National Marrow Donor
Program’s classiﬁcation of HLAmatching status was used for unrelated donor
transplant recipients (well matched, partially matched, or mismatched) [13].
The goal of our case-control study was to assess potential risk factors for
developing AVN in children and adolescents after allogeneic HCT. For
comparing characteristics between patients and control subjects, we used
the chi-square or Fisher’s test (as applicable) for categorical variables and
Wilcoxon 2-sample test for continuous variables. To evaluate risk factors, we
performedmultivariable analyses using conditional logistic regression on all
matched sets. The following variables were considered in this analysis: age
at transplantation, gender, diagnosis, disease status, conditioning regimen
intensity, dose of TBI, donor source, and history of GVHD before AVN. If
feasible, categories with a small number of patients were combined with
related categories. Patients receiving transplant from HLA-mismatched
related donors (n ¼ 23), patients with unknown conditioning regimen in-
tensity (n ¼ 2), and patients with unknown date of GVHD onset (n ¼ 14)
were excluded from the risk factor analysis.
All P-values are 2-sided. All analyses were carried out using SAS statis-
tical software (SAS Institute Inc., Cary, NC).
RESULTS
Characteristics of Patients and Control Subjects
Table 1 shows the characteristics of the 160 AVN patients
and 478 control subjects. The median age at transplantation
was 15 years for patients and 8 years for control subjects. The
primary diagnosis of nonmalignant disorder was higher in
the control group (32%) comparedwith AVN patients (13%). A
greater proportion of AVN patients had received TBI con-
taining myeloablative regimen compared with control sub-
jects (65% versus 48%). Related, unrelated, and umbilical cord
blood donors were used in 21%, 64%, and 16% of AVN patients
and 11%, 69%, and 21% of control subjects, respectively. Fifty-
six percent of patients had a history of chronic GVHD before
the onset of AVN compared with 49% in the control group.
Among AVN patients, the median time from HCT to the
onset of AVNwas 14months (range,<1 to 172months). In 37%
of patients AVN occurred within 1 year of HCT, in 59% AVN
occurred 1 to 5 years after HCT, and in 4% it occurred more
than 5 years after transplantation. Detailed information was
available for 59 patients to completely characterize the extent
of joint involvement by AVN. Among these patients, collec-
tively 119 joints were affected by AVN with a median of 2
joints (range, 1 to 6). Femoral head (82%) was the most com-
mon site of involvement and was followed by the knee joint
(78%), the vertebral column (12%), and the ankle joint (10%).
AVN of the shoulder joint was rare (5% of patients). Pathologic
fracture was the initial presentation of AVN in 3 patients.
We also evaluated the characteristics of patients included
in our study by donor source (related ¼ 83 patients [41%
patients, 59% control subjects], unrelated ¼ 432 patients
[23% patients, 77% control subjects], umbilical cord
blood¼ 123 [20% patients, 80% control subjects]). Therewere
notable differences among related, unrelated, and umbilical
Table 1
Characteristics of AVN Patients and Their Control Subjects (Matched by
Transplant Center, Year of Transplant, and Duration of Follow-Up)
Characteristics Patients Control
Subjects
P
Number of patients 160 478
Number of centers 54 52
Age at transplant, yr, median (range) 15 (2-21) 8 (<1-21) <.01
Age at transplant, yr <.01
<5 5 (3) 154 (32)
5-9 16 (10) 112 (23)
10-14 56 (35) 94 (20)
15-21 83 (52) 118 (25)
Patient gender <.01
Male 78 (49) 289 (60)
Female 82 (51) 189 (40)
Lansky/Karnofsky score before
transplant
.99
<90 22 (15) 66 (15)
90 121 (85) 362 (85)
Missing 17 50
Patient race .88
White 128 (80) 385 (81)
Non-White 32 (20) 93 (19)
Disease <.01
Acute myeloid leukemia 47 (29) 119 (25)
Acute lymphoblastic leukemia 57 (36) 128 (27)
Chronic myeloid leukemia 14 (9) 31 (6)
Myelodysplastic syndrome 18 (11) 32 (7)
Non-Hodgkin lymphoma 2 (1) 15 (3)
Hodgkin lymphoma 1 (1) 0
Severe aplastic anemia 11 (7) 42 (9)
Inherited abnormality of
erythrocyte differentiation
5 (3) 36 (8)
SCID and other immune system
disorders
2 (1) 42 (9)
Inherited disorder of metabolism 2 (1) 20 (4)
Histiocytic disorders 1 (1) 13 (3)
Disease risk before transplant <.01
Early 62 (39) 130 (27)
Intermediate 55 (34) 147 (31)
Advanced 22 (14) 43 (9)
Nonmalignant disease 21 (13) 153 (32)
Unknown 0 5 (1)
Interval from diagnosis to transplant,
mo
.02
<6 60 (38) 135 (28)
6-11 31 (19) 100 (21)
12 66 (41) 205 (43)
Unknown 3 (2) 38 (8)
Year of transplant* d
1990-1994 5 (3) 19 (4)
1995-1999 13 (8) 40 (8)
2000-2004 60 (38) 215 (45)
2005-2008 82 (51) 204 (43)
Total TBI dose, cGy <.01
No TBI 45 (28) 191 (40)
<1200 cGy 14 (9) 53 (11)
 1200 cGy 100 (63) 234 (49)
Missing 1 0
Conditioning regimen intensity <.01
Myeloablative (with TBI) 102 (65) 229 (48)
Myeloablative (no TBI) 27 (17) 68 (14)
Nonmyeloablative/reduced
intensity
8 (5) 28 (6)
Nonmalignant diseases 21 (13) 153 (32)
Missing 2 0
Graft type .38
Bone marrow 93 (58) 268 (56)
Peripheral blood  bone marrow 42 (26) 112 (23)
Umbilical cord bloody 25 (16) 98 (21)
Donor type .01
HLA-matched sibling 23 (14) 37 (8)
Other related 11 (7) 12 (3)
Well-matched unrelated 60 (38) 194 (41)
Partially/mismatched unrelated 40 (25) 135 (28)
(Continued)
Table 1
(continued)
Characteristics Patients Control
Subjects
P
Unrelated, match unknown 1 (1) 2 (<1)
Umbilical cord blood 25 (16) 98 (21)
GVHD prophylaxis .51
FK506 þ MMF  others 13 (8) 26 (5)
FK506 þ MTX  others (except
MMF)
28 (18) 86 (18)
FK506  others (except MTX, MMF) 9 (6) 18 (4)
CSA þ MMF  others 13 (8) 41 (9)
CSA þ MTX  others (except MMF) 58 (36) 161 (34)
CSA  others (except MTX, MMF) 24 (15) 72 (15)
T cell depletion 10 (6) 56 (12)
Other/unknown 5 (3) 18 (4)
History of GVHDz .05
No GVHD 43 (27) 179 (37)
Acute GVHD only 28 (18) 66 (14)
Chronic  acute GVHD 89 (56) 233 (49)
Interval from transplant to AVN, mo,
median (range)
14 (<1-172) d
Follow-up of survivors, mo, median
(range)*
61 (11-194) 63 (7-225)
SCID, severe combined immunodeﬁciency; MMF, mycophenolate mofetil;
MTX, methotrexate; CSA, cyclosporine.
Values are total number of incidences with percents in parentheses, unless
otherwise noted.
* Variable used for matching patients and control subjects.
y Includes 6 related umbilical cord blood transplants (1 patient, 5 control
subjects).
z History of GVHD before AVN for patients; for control subjects, any
history of GVHD within the corresponding follow-up time period for the
matched patient.
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(14 years versus 12 years versus 6 years, P < .001), time from
diagnosis to transplant (HCT within 6 months of diagnosis in
53% versus 25% versus 35% patients, P < .001), use of TBI as
part of conditioning (45% versus 68% versus 57%, P < .001),
and history of chronic GVHD (37% versus 55% versus 43%,
P < .001), respectively. There were also differences in GVHD
prophylaxis regimens by donor source; for example, 2% of
related donor, 15% of unrelated donor, and 0% of umbilical
cord blood HCT recipients received ex vivo or in vivo T cell
depletion to prevent GVHD.
Risk Factor Analysis
Table 2 shows the results of conditional logistic regression
analysis. Risk factors independently associated with
increased risks for AVN were older age at HCT (>5 years),
female gender, and a history of chronic GVHD. The use of
nonmyeloablative/reduced-intensity regimens for condi-
tioning patients with malignant disease and the diagnosis of
nonmalignant disease, regardless of conditioning intensity,
were associated with statistically signiﬁcantly lower risks for
AVNwhen comparedwith the use of myeloablative regimens
for conditioning patients with malignant diseases. The risks
of AVN were similar in patients who received and did not
receive TBI as part of myeloablative conditioning for malig-
nant diseases. Interestingly, the use of unrelated donors was
observed to be associatedwith a lower risk of AVN.We tested
for and found no signiﬁcant interactions between donor
source and other variables (including GVHD) considered in
multivariate analyses.
DISCUSSION
Our study identiﬁes important risk factors for AVN in a
large cohort of pediatric allogeneic HCT recipients and lays
Table 2
Risk Factors Identiﬁed to be Independently Associated with Post-Transplant AVN on Conditional Logistic Regression Analysis
Risk Factor Category* Patients n (%) Control Subjects n (%) Hazard Ratio (95% CI) P
Age <5 yr 5 (3) 148 (33) 1.00 <.01*
5-9 yr 14 (10) 103 (23) 3.40 (1.17-9.89) .03
10-21 yr 128 (87) 201 (44) 19.83 (7.23-54.42) <.01
Gender Male 71 (48) 271 (60) 1.00
Female 76 (52) 181 (40) 1.65 (1.05-2.58) .03
Diagnosis and conditioning Malignant disease, MA regimen, TBI 97 (66) 215 (48) 1.00 <.01y
Malignant disease, MA regimen, no TBI 22 (15) 64 (14) .64 (.32-1.26) .20
Malignant disease, NMA/RIC regimen 7 (5) 25 (6) .31 (.11-.88) .03
Nonmalignant disease 21 (14) 148 (33) 0.30 (0.14-0.63) <.01
Donor HLA-identical sibling 23 (16) 36 (8) 1.00 <.01y
Unrelated 100 (68) 321 (71) .26 (.12-.56) <.01
Umbilical cord blood 24 (16) 95 (21) .41 (.17-1.03) .06
GVHD None 41 (28) 175 (39) 1.00 .08y
Acute GVHD only 23 (16) 63 (14) 1.45 (.71-2.97) .31
Chronic GVHD  acute GVHD 83 (56) 214 (47) 1.88 (1.09-3.23) .02
CI, conﬁdence interval; MA, myeloablative; NMA/RIC, nonmyeloablative/reduced intensity.
* Patients receiving transplant from HLA-mismatched related donors (n ¼ 23), patients with unknown conditioning regimen intensity (n ¼ 2), and patients
with unknown date of GVHD onset (n ¼ 14) were excluded from the risk factor analysis.
y Overall P value.
Table 3
Summary of Contemporary Studies Investigating Risk Factors for AVN after
Allogeneic HCT in Children
Reference AVN
Patients
Median
Age (yr)
Risk Factors
Socie
et al.
(1997)
[8]
77 (21
patients
aged < 20
yr)
25 Age 16 yr at HCT, diagnosis of aplastic
anemia or acute leukemia, acute GVHD,
chronic GVHD
Kaste
et al.
(2004)
[23]
19 (all
children)
10 Female gender
Faraci
et al.
(2006)
[24]
43 (all
children)
13* Chronic GVHD, TBI, older age at HCT
Leung
et al.
(2007)
[14]
20 (all
children)
10 Female gender, older age at HCT
Campbell
et al.
(2009)
[7]
75 (46
patients
aged < 35
yr; 73%
allogeneic
HCT)
34 Male gender, chronic GVHD, exposure
to calcineurin inhibitors and
prednisone
McAvoy
et al.
(2010)
[6]
66 (15
patients
aged  18
yr)
29 Cumulative dose of corticosteroids
Sharma
et al.
(2012)
[15]
44 (all
children)
11 Age  10 yr at HCT, pre-HCT history of
AVN
Present
study
160 (all
children)
15 Older age at HCT, female gender,
chronic GVHD, myeloablative
conditioning regimen
* Mean age.
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vention of AVN in this population. We observed that risks
increased with recipient age at transplantation. This has
been reported by other relatively smaller studies in pediatric
allogeneic HCT recipients [14,15] and suggests that children
within the age group when rapid bone growth occurs are
most susceptible to AVN. Other identiﬁed risk factors,
including female gender and history of chronic GVHD, were
similar to that previously reported by studies that have pri-
marily included adults (Table 3) [3,5,9,16-18]. Of note, the
observations from relatively smaller published studies are
inconsistent when describing the gender-related differences
in risk of AVN. Some studies have reported an increase risk
among females, whereas others have demonstrated an
increased risk in males, and some have failed to show a
gender preference.
The risks of AVN with nonmyeloablative/reduced-
intensity conditioning have not been previously described,
and an important ﬁnding from our study is our observation
that use of less-intense conditioning regimens is associated
with lower risks for AVN. Compared with recipients of
myeloablative conditioning, patients with malignant dis-
eases receiving nonmyeloablative/reduced-intensity regi-
mens had a 70% lower risk of developing AVN. Similarly,
patients with nonmalignant diseases, who tend to receive
conditioning of comparable intensity as reduced-intensity
preparative regimens, had signiﬁcantly lower risks of
developing AVN. The decision to pursue myeloablative or
nonmyeloablative/reduced-intensity conditioning for trans-
plantation is frequently complex and has to take into account
various factors such as diagnosis, disease status, performance
status, and presence of comorbidities. Risk for complications
is also a consideration, and our studywill inform the decision
process for patients who are at high risk for developing AVN.
The lower risk of AVN in patients receiving unrelated
donor HCT is in contrast to what has been previously re-
ported in the literature [1]. We did not ﬁnd any signiﬁcant
interactions between donor source and GVHD. This may be
due to different exposures; for example, regimens for pre-
vention or treatment of GVHD in unrelated donor HCT re-
cipients may contain no corticosteroids or lesser doses of
corticosteroids in combination with other agents. Indeed, a
greater proportion of unrelated donor recipients had
received T cell depletion for GVHD prophylaxis in our study.It is also possible that ascertainment bias might partly
explain this ﬁnding. Diagnostic testing for AVN is more likely
to occur among patients who are followed up long term at
transplant centers, where providers are more aware of this
complication. Centers may preferentially follow more unre-
lated donor over HLA-identical sibling donor HCT recipients,
especially because the former have a greater likelihood of
developing chronic GVHD and need ongoing specialized care
at the transplant center. Indeed, we had more control
X. Li et al. / Biol Blood Marrow Transplant 20 (2014) 577e592 591subjects whowere unrelated donor HCT recipients than HLA-
identical sibling donor HCT recipients (control subjects
included 11% related donor, 69% unrelated donor, and 21%
umbilical cord blood recipients). Other risk factors that are
not captured by the CIBMTR may also explain this observa-
tion and need further evaluation in future studies.
Some limitations of our study have to be considered. AVN
is frequently an under-diagnosed and hence under-reported
late complication of transplantation. Exposure to calcineurin
inhibitors and corticosteroids and the cumulative dose of
corticosteroids have been shown to be an important risk
factor for AVN [6,7,19]. Similarly, pretransplant chemo-
therapy, radiation, and corticosteroid exposures and post-
transplant events such as endocrine late effects may also
modulate the risks of post-transplant AVN. The CIBMTR does
not routinely collect data on these variables, and these risk
factors could not be evaluated in our study. Even though our
study represents the largest analysis of AVN in pediatric HCT
recipients, we were not able to evaluate some risk factors
because of the small number of patients (eg, speciﬁc di-
agnoses where pre- and post-transplant exposures may be
different). One such notable risk factor is the diagnosis of
acute lymphoblastic leukemia, which is a well-established
risk factor for AVN in pediatric patients who do not receive
a transplant. Centers may have different practices for follow-
up of patients post-transplantation and for diagnosis and
screening for AVN. To account for this, we tried to identify
control subjects from the same centers as patients or from
other centers that had reported a case (85% of case-control
pairs were from the same center). We excluded patients
with a pre-HCT diagnosis of AVN. However, subclinical AVN
may begin pretransplantation and manifest clinically post-
transplantation.
In conclusion, older age at HCT, female gender, exposure
to myeloablative conditioning regimen, and chronic GVHD
are risk factors for AVN after allogeneic HCT in children and
adolescents. Screening strategies speciﬁcally for patients at
high risk for developing AVN with early initiation of in-
terventions (eg, physical therapy, limited surgery) might
mitigate the morbidity associated with this complication.
Our study, by highlighting important risk factors, lays the
foundation for future research in this area. Clinicians taking
care of pediatric allogeneic HCT survivors should maintain
vigilance for this complication and have a high index of
suspicion for AVN in patients with risk factors who present
with new bone-related symptoms. Until more research is
available, clinicians should follow published consensus
guidelines for long-term follow-up that recommend early
screening for AVN with magnetic resonance imaging in pa-
tients with such symptoms [20-22].ACKNOWLEDGMENTS
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